ReviewAmerican journal of respiratory and critical care medicine2016
Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis.
Review in American journal of respiratory and critical care medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Article
- Molecular Endotypes of Idiopathic Pulmonary Fibrosis: A Latent Class Analysis of Two Multicenter Observational Cohorts.American journal of respiratory and critical care medicine · 2024Observational
- Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone.Heliyon · 2023Article
- Targeted imaging of very late antigen-4 for noninvasive assessment of lung inflammation-fibrosis axis.EJNMMI research · 2023Article
- Article
- Lung Myofibroblasts Promote Macrophage Profibrotic Activity through Lactate-induced Histone Lactylation.American journal of respiratory cell and molecular biology · 2021Article
- Parametric Time-to-Event Model for Acute Exacerbations in Idiopathic Pulmonary Fibrosis.CPT: pharmacometrics & systems pharmacology · 2020Article
- Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF).Journal of thoracic disease · 2019Review
- Fibrosing interstitial lung diseases: knowns and unknowns.European respiratory review : an official journal of the European Respiratory Society · 2019Review
- Mechanisms for the Resolution of Organ Fibrosis.Physiology (Bethesda, Md.) · 2019Review
- Idiopathic Pulmonary Fibrosis (IPF): An Overview.Journal of clinical medicine · 2018Review
- Is personalized medicine a realistic goal in idiopathic pulmonary fibrosis?Expert review of respiratory medicine · 2018Article
- Towards a global initiative for fibrosis treatment (GIFT).ERJ open research · 2017Article
- An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases.Annals of the American Thoracic Society · 2017Article
- Update in Interstitial Lung Disease 2016.American journal of respiratory and critical care medicine · 2017Article
- The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes.Scientific reports · 2017Observational
- Fibroblast growth factors and pulmonary fibrosis: it's more complex than it sounds.The Journal of pathology · 2017Article
- Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis.Frontiers in medicine · 2017Review
- Role of pirfenidone in the management of pulmonary fibrosis.Therapeutics and clinical risk management · 2017Review
- The diagnosis of idiopathic pulmonary fibrosis: current and future approaches.The Lancet. Respiratory medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Precision medicine is defined by the National Institute of Health's Precision Medicine Initiative Working Group as an approach to disease treatment that takes into account individual variability in genes, environment, and lifestyle. There has been increased interest in applying the concept of precision medicine to idiopathic pulmonary fibrosis, in particular to search for genetic and molecular biomarker-based profiles (so called endotypes) that identify mechanistically distinct disease subgroups. The relevance of precision medicine to idiopathic pulmonary fibrosis is yet to be established, but we believe that it holds great promise to provide targeted and highly effective therapies to patients. In this manuscript, we describe the field's nascent efforts in genetic/molecular endotype identification and how environmental and behavioral subgroups may also be relevant to disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.